Dr Reddy's Laboratories has warned that proposed United States tariffs on imported generic medicines could result in significantly higher prices for American consumers. The United States plans to implement major duties on these pharmaceutical imports, with rates expected to climb as high as 200% in the coming years.
In response to the proposed policy, the pharmaceutical company stated that shifting its manufacturing operations to the United States is currently considered impractical. The planned tariff increases are anticipated to be a difficult financial burden for consumers purchasing medications in the US market.
In-depth summary · AI, neutral